LitAlert ~~ GeneLit.com

    • Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    • Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E.
    • Eur J Cancer. 2020 Sep 22;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub ahead of print.
    • Epigenetic based synthetic lethal strategies in human cancers.
    • Gao A, Guo M.
    • Biomark Res. 2020 Sep 15;8:44. doi: 10.1186/s40364-020-00224-1.